Compare RCUS & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | TWST |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2018 | 2018 |
| Metric | RCUS | TWST |
|---|---|---|
| Price | $26.12 | $63.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $30.27 | ★ $46.88 |
| AVG Volume (30 Days) | 999.3K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | N/A | ★ N/A |
| Revenue | $247,000,000.00 | ★ $376,572,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | $45.62 | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $7.06 | $23.30 |
| 52 Week High | $26.40 | $65.10 |
| Indicator | RCUS | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 72.03 |
| Support Level | $19.62 | $41.85 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.56 | 3.28 |
| MACD | 0.30 | 1.37 |
| Stochastic Oscillator | 69.54 | 87.59 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.